AR007097A1 - Biarilacetilenos inhibidores de la metaloproteasa de matriz, una composicion que tiene actividad inhibitoria de la metaloproteasa de matriz yel uso de dichos biarilacetilenos en la manufactura de un medicamento. - Google Patents
Biarilacetilenos inhibidores de la metaloproteasa de matriz, una composicion que tiene actividad inhibitoria de la metaloproteasa de matriz yel uso de dichos biarilacetilenos en la manufactura de un medicamento.Info
- Publication number
- AR007097A1 AR007097A1 ARP970101977A ARP970101977A AR007097A1 AR 007097 A1 AR007097 A1 AR 007097A1 AR P970101977 A ARP970101977 A AR P970101977A AR P970101977 A ARP970101977 A AR P970101977A AR 007097 A1 AR007097 A1 AR 007097A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- matrix
- matrix metaloprotease
- biarylacetilene
- biarylacethylene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Steroid Compounds (AREA)
Abstract
Se presentan compuestos inhibitorios de la metaloproteasa de matriz, composiciones farmacéuticas de los mismos y el uso de dichos compuestos parapreparar un medicamento útil. Los compuestos tienen la fórmula (I), donde R15 es seleccionadoen tre el grupo que consiste en HOCH2, MeOCH2, (n-Pr)2NCH2,CH3CO2CH2, EtOCO2CH2, HO(CH2)2, CH3CO2(CH2)2, HO2C(CH2)2, OHC(CH2)3, HO(CH2)4, 3-HO-Ph, y PhCH2OCH2; y R16 es seleccionado entre las fórmulas (II). Estoscompuestos son útiles para inhibirlas m etaloproteasas de matriz y, por lo tanto, para combatir los trastornos a los cuales contribuyen las MMP, talescomo la osteoartritis, la artritis reumatoidea, la artritis séptica, las enfermedades periodontales, las úlceras decórnea, la p roteinuria, laenfermedad de aneurisma aórtico, la epidermólisis vesicular distrófica, los tratarnos que producen respuestas inflamatorias, las osteopenias en las quemedia la actividad de MMP, la enfermedad de la articulacióntemporomandibular, l as enfermedades desmielinizantes del sistema nervioso; las metástasis detumores o la pérdida degenerativa de cartílago posterior a la lesión articular traumática, y la trombosis coronaria a partir de la ruptura deplacaateroesclerótica.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64502896A | 1996-05-15 | 1996-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR007097A1 true AR007097A1 (es) | 1999-10-13 |
Family
ID=24587368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970101977A AR007097A1 (es) | 1996-05-15 | 1997-05-12 | Biarilacetilenos inhibidores de la metaloproteasa de matriz, una composicion que tiene actividad inhibitoria de la metaloproteasa de matriz yel uso de dichos biarilacetilenos en la manufactura de un medicamento. |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP0912496A1 (es) |
JP (1) | JP3090957B2 (es) |
CN (1) | CN1139570C (es) |
AR (1) | AR007097A1 (es) |
AU (1) | AU710759B2 (es) |
BR (1) | BR9709077A (es) |
CA (1) | CA2253796C (es) |
CO (1) | CO5080759A1 (es) |
HN (1) | HN1997000088A (es) |
HR (1) | HRP970245B1 (es) |
ID (1) | ID16910A (es) |
PA (1) | PA8429301A1 (es) |
SV (1) | SV1997000035A (es) |
TN (1) | TNSN97084A1 (es) |
TW (1) | TW381079B (es) |
WO (1) | WO1997043245A1 (es) |
YU (1) | YU18697A (es) |
ZA (1) | ZA974031B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6288063B1 (en) | 1998-05-27 | 2001-09-11 | Bayer Corporation | Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors |
AR035478A1 (es) * | 1999-01-27 | 2004-06-02 | Wyeth Corp | Acido amida-hidroxamico, acido acetilenico, beta-sulfonamido y fosfinico como inhibidores de la tace, uso de los mismos para la manufactura de un medicamento y composicion farmaceutica que los contiene |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
EP1031349A1 (en) * | 1999-02-25 | 2000-08-30 | Bayer Aktiengesellschaft | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases |
US7141607B1 (en) | 2000-03-10 | 2006-11-28 | Insite Vision Incorporated | Methods and compositions for treating and inhibiting retinal neovascularization |
US8765814B2 (en) * | 2010-07-08 | 2014-07-01 | Kaken Pharmaceutical Co., Ltd. | N-hydroxyformamide derivative and medicament containing same |
EP3126339A1 (de) | 2014-04-03 | 2017-02-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung |
US20170114049A1 (en) | 2014-04-03 | 2017-04-27 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratory tract diseases |
CA2944617A1 (en) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3784701A (en) * | 1970-09-21 | 1974-01-08 | American Cyanamid Co | Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain |
DE2112716A1 (de) * | 1971-03-17 | 1972-10-05 | Thomae Gmbh Dr K | Neue 4-(4-Biphenylyl)-4-oxobuttersaeuren,ihre Salze und ihre Ester |
US5789434A (en) * | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
-
1997
- 1997-05-09 ZA ZA9704031A patent/ZA974031B/xx unknown
- 1997-05-09 HR HR970245A patent/HRP970245B1/xx not_active IP Right Cessation
- 1997-05-09 TN TNTNSN97084A patent/TNSN97084A1/fr unknown
- 1997-05-09 CO CO97025172A patent/CO5080759A1/es unknown
- 1997-05-12 HN HN1997000088A patent/HN1997000088A/es unknown
- 1997-05-12 CN CNB971964564A patent/CN1139570C/zh not_active Expired - Fee Related
- 1997-05-12 TW TW086106283A patent/TW381079B/zh not_active IP Right Cessation
- 1997-05-12 BR BR9709077A patent/BR9709077A/pt not_active Application Discontinuation
- 1997-05-12 AR ARP970101977A patent/AR007097A1/es unknown
- 1997-05-12 WO PCT/US1997/007921 patent/WO1997043245A1/en not_active Application Discontinuation
- 1997-05-12 CA CA002253796A patent/CA2253796C/en not_active Expired - Fee Related
- 1997-05-12 SV SV1997000035A patent/SV1997000035A/es unknown
- 1997-05-12 YU YU18697A patent/YU18697A/sr unknown
- 1997-05-12 PA PA19978429301A patent/PA8429301A1/es unknown
- 1997-05-12 AU AU29386/97A patent/AU710759B2/en not_active Ceased
- 1997-05-12 JP JP09540980A patent/JP3090957B2/ja not_active Expired - Fee Related
- 1997-05-12 EP EP97923622A patent/EP0912496A1/en not_active Withdrawn
- 1997-05-14 ID IDP971606A patent/ID16910A/id unknown
Also Published As
Publication number | Publication date |
---|---|
JP3090957B2 (ja) | 2000-09-25 |
CA2253796A1 (en) | 1997-11-20 |
HRP970245B1 (en) | 2002-06-30 |
EP0912496A1 (en) | 1999-05-06 |
HRP970245A2 (en) | 1998-04-30 |
SV1997000035A (es) | 1999-01-14 |
CN1139570C (zh) | 2004-02-25 |
CO5080759A1 (es) | 2001-09-25 |
PA8429301A1 (es) | 2000-05-24 |
CA2253796C (en) | 2003-10-28 |
ID16910A (id) | 1997-11-20 |
BR9709077A (pt) | 1999-08-03 |
TW381079B (en) | 2000-02-01 |
CN1225623A (zh) | 1999-08-11 |
AU710759B2 (en) | 1999-09-30 |
YU18697A (en) | 1999-11-22 |
ZA974031B (en) | 1998-02-19 |
TNSN97084A1 (fr) | 2005-03-15 |
AU2938697A (en) | 1997-12-05 |
WO1997043245A1 (en) | 1997-11-20 |
JPH11511179A (ja) | 1999-09-28 |
HN1997000088A (es) | 1997-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE208397T1 (de) | Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe | |
AR029383A1 (es) | Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes | |
BR9611015A (pt) | Composto, composição farmacêutica e processo para o tratamento de uma doença inflamatória suscetìvel ao tratamento com um agente não-tóxico anti-inflamatório não-esteróide, sal farmaceuticamente aceitável, utilização de um composto | |
DE60018040D1 (de) | Polymorphische kristalline formen von celekoxib | |
GB9930610D0 (en) | Tricyclic vascular damaging agents | |
BR0312280A (pt) | Composto ou um sal, solvato, solvato de tal sal ou uma prodroga do mesmo faarmaceuticamente aceitável, processo para prepará-lo, composição farmacêutica, uso do composto, métodos para produzir um efeito inibidor da absorção de colesterol, e para tratar condições hiperlipidêmicas em um animal de sangue quente, tal como o homem, que necessita de tal tratamento, combinação, e, uso desta | |
BR9509683A (pt) | Compostos e processos para tratar uma condição clínica em um mamífero para tratar uma condição hiperlipidêmica em um manífero e para a preparação de um composto | |
AR007097A1 (es) | Biarilacetilenos inhibidores de la metaloproteasa de matriz, una composicion que tiene actividad inhibitoria de la metaloproteasa de matriz yel uso de dichos biarilacetilenos en la manufactura de un medicamento. | |
AR022423A1 (es) | Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento | |
UY23537A1 (es) | Benzopirano y antagonistas de ltb4 relacionados | |
AR007098A1 (es) | Inhibidores de la metaloproteasa de matriz, composiciones que los comprenden, y uso de los mismos para preparar composiciones farmaceuticas | |
ES2038172T3 (es) | Procedimiento para preparar carboxamidas heterociclicas. | |
BG102471A (en) | Aromatic ketoacids and their derivatives as inhibitors of matrix metalloproteinases | |
AR007100A1 (es) | Inhibicion de las metaloproteasas de matriz por compuestos de fenilalquilo sustituido y el uso de los mismos para la preparacion de un medicamento. | |
ID28365A (id) | Turunan produk alami yang baru | |
AR007096A1 (es) | Compuesto inhibidor de la metaloproteasa de matriz metodo para inhibir su actividad, una composicion que lo contiene y uso de dichos compuestos para preparar composiciones farmaceuticas | |
ES2095894T3 (es) | Derivados de galactomanano para el revestimiento o la incrustacion de productos activos farmaceuticos. | |
IL73849A0 (en) | Pharmaceutical compositions containing phospholipids and oxicam derivatives and their production | |
ATE169635T1 (de) | Therapeutische verbindungen für die behandlung von krankheiten, die mit einem glutathion-defizit assoziiert sind, herstellungsprozess und diese enthaltene pharmazeutische zusammensetzungen | |
PA8429601A1 (es) | Inhibicion de las metaloproteinasas de matriz por acidos 2-(w-aroilalquil)-4-biaril-4-oxobutiricos. | |
MX9206042A (es) | Nuevos derivados de tiadiazinonas, proceso para su fabricacion y preparado farmaceutico que los contiene | |
EP0913396A3 (de) | Sulfonamid-substituierte Benzopyranderivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen | |
ECSP972114A (es) | Biarilacetilenos como inhibidores de la metaloproteasa de matriz | |
ATE66208T1 (de) | Diarylmethan-sulfonamid-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
ECSP972111A (es) | Inhibidores de la metaloproteinasas de matriz por acidos 2-(aroilalquil)-4 biaril-4- oxobutiricos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |